TARDBP and amyotrophic lateral sclerosis: Notably, multiple inhibitors of the MAPK pathway have been tested in various models of ALS, including those targeting MAP4K, which have been shown to increase motor neuron survival time in SOD1 and mutant TDP-43 induced pluripotent stem cell lines [90].